BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1102 related articles for article (PubMed ID: 25770314)

  • 21. Prevalence of stroke and the need for thromboprophylaxis in young patients with atrial fibrillation: a cohort study.
    Lin AH; Oakley LS; Phan HL; Shutt BJ; Birgersdotter-Green U; Francisco GM
    J Cardiovasc Med (Hagerstown); 2014 Mar; 15(3):189-93. PubMed ID: 24625564
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ischemic stroke risk estimation in patients without oral anticoagulation: an observational cohort study based on secondary data from Germany.
    Wicke FS; Schaller MA; Karymova K; Beyer M; Müller BS
    BMC Cardiovasc Disord; 2019 Apr; 19(1):94. PubMed ID: 31014253
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Atrial fibrillation patients categorized as "not for anticoagulation" according to the 2014 Canadian Cardiovascular Society algorithm are not "low risk".
    Lip GY; Nielsen PB; Skjøth F; Rasmussen LH; Larsen TB
    Can J Cardiol; 2015 Jan; 31(1):24-8. PubMed ID: 25547546
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk Levels and Adverse Clinical Outcomes Among Patients With Nonvalvular Atrial Fibrillation Receiving Oral Anticoagulants.
    Lip GYH; Murphy RR; Sahiar F; Ingall TJ; Dhamane AD; Ferri M; Hlavacek P; Preib MT; Keshishian A; Russ C; Rosenblatt L; Yuce H; Deitelzweig S
    JAMA Netw Open; 2022 Aug; 5(8):e2229333. PubMed ID: 36044214
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The value of the European society of cardiology guidelines for refining stroke risk stratification in patients with atrial fibrillation categorized as low risk using the anticoagulation and risk factors in atrial fibrillation stroke score: a nationwide cohort study.
    Lip GYH; Nielsen PB; Skjøth F; Lane DA; Rasmussen LH; Larsen TB
    Chest; 2014 Nov; 146(5):1337-1346. PubMed ID: 25086251
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Renal dysfunction, stroke risk scores (CHADS2, CHA2DS2-VASc, and R2CHADS2), and the risk of thromboembolic events after catheter ablation of atrial fibrillation: the Leipzig Heart Center AF Ablation Registry.
    Kornej J; Hindricks G; Kosiuk J; Arya A; Sommer P; Husser D; Rolf S; Richter S; Piorkowski C; Gaspar T; Lip GY; Bollmann A
    Circ Arrhythm Electrophysiol; 2013 Oct; 6(5):868-74. PubMed ID: 24047706
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is an Oral Anticoagulant Necessary for Young Atrial Fibrillation Patients With a CHA2DS2-VASc Score of 1 (Men) or 2 (Women)?
    Hung Y; Chao TF; Liu CJ; Tuan TC; Lin YJ; Chang SL; Lo LW; Hu YF; Liao JN; Chung FP; Lin WY; Lin WS; Cheng SM; Chen TJ; Lip GY; Chen SA
    J Am Heart Assoc; 2016 Oct; 5(10):. PubMed ID: 27702803
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CHA2DS2-VASc score is directly associated with the risk of pulmonary embolism in patients with atrial fibrillation.
    Saliba W; Rennert G
    Am J Med; 2014 Jan; 127(1):45-52. PubMed ID: 24384101
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Female Sex Is a Risk Modifier Rather Than a Risk Factor for Stroke in Atrial Fibrillation: Should We Use a CHA
    Nielsen PB; Skjøth F; Overvad TF; Larsen TB; Lip GYH
    Circulation; 2018 Feb; 137(8):832-840. PubMed ID: 29459469
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reliable identification of "truly low" thromboembolic risk in patients initially diagnosed with "lone" atrial fibrillation: the Belgrade atrial fibrillation study.
    Potpara TS; Polovina MM; Licina MM; Marinkovic JM; Prostran MS; Lip GY
    Circ Arrhythm Electrophysiol; 2012 Apr; 5(2):319-26. PubMed ID: 22319004
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Time Trends of Aspirin and Warfarin Use on Stroke and Bleeding Events in Chinese Patients With New-Onset Atrial Fibrillation.
    Guo Y; Wang H; Tian Y; Wang Y; Lip GYH
    Chest; 2015 Jul; 148(1):62-72. PubMed ID: 25501045
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and Economic Implications of Apixaban Versus Aspirin in the Low-Risk Nonvalvular Atrial Fibrillation Patients.
    Lip GY; Lanitis T; Mardekian J; Kongnakorn T; Phatak H; Dorian P
    Stroke; 2015 Oct; 46(10):2830-7. PubMed ID: 26316345
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Age Threshold for Increased Stroke Risk Among Patients With Atrial Fibrillation: A Nationwide Cohort Study From Taiwan.
    Chao TF; Wang KL; Liu CJ; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Chung FP; Liao JN; Chen TJ; Chiang CE; Lip GY; Chen SA
    J Am Coll Cardiol; 2015 Sep; 66(12):1339-47. PubMed ID: 26383720
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy.
    Lip GY; Skjøth F; Nielsen PB; Larsen TB
    Thromb Haemost; 2015 Oct; 114(4):826-34. PubMed ID: 26223245
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Validation of a Modified CHA2DS2-VASc Score for Stroke Risk Stratification in Asian Patients With Atrial Fibrillation: A Nationwide Cohort Study.
    Chao TF; Lip GY; Liu CJ; Tuan TC; Chen SJ; Wang KL; Lin YJ; Chang SL; Lo LW; Hu YF; Chen TJ; Chiang CE; Chen SA
    Stroke; 2016 Oct; 47(10):2462-9. PubMed ID: 27625386
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.
    Piccini JP; Stevens SR; Chang Y; Singer DE; Lokhnygina Y; Go AS; Patel MR; Mahaffey KW; Halperin JL; Breithardt G; Hankey GJ; Hacke W; Becker RC; Nessel CC; Fox KA; Califf RM;
    Circulation; 2013 Jan; 127(2):224-32. PubMed ID: 23212720
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Net Clinical Benefit for Oral Anticoagulation, Aspirin, or No Therapy in Nonvalvular Atrial Fibrillation Patients With 1 Additional Risk Factor of the CHA2DS2-VASc Score (Beyond Sex).
    Lip GY; Skjøth F; Rasmussen LH; Nielsen PB; Larsen TB
    J Am Coll Cardiol; 2015 Jul; 66(4):488-90. PubMed ID: 26205604
    [No Abstract]   [Full Text] [Related]  

  • 38. Predictive value of the CHA2DS2-VASc score in atrial fibrillation patients at high risk for stroke despite oral anticoagulation.
    Jover E; Roldán V; Gallego P; Hernández-Romero D; Valdés M; Vicente V; Lip GY; Marín F
    Rev Esp Cardiol (Engl Ed); 2012 Jul; 65(7):627-33. PubMed ID: 22609214
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Contemporary Trends in Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Low to Moderate Risk of Stroke After Guideline-Recommended Change in Use of the CHADS
    Katz DF; Maddox TM; Turakhia M; Gehi A; O'Brien EC; Lubitz SA; Turchin A; Doros G; Lei L; Varosy P; Marzec L; Hsu JC
    Circ Cardiovasc Qual Outcomes; 2017 May; 10(5):. PubMed ID: 28506981
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Young Male Patients with Atrial Fibrillation and CHA2DS2-VASc Score of 1 May Not Need Anticoagulants: A Nationwide Population-Based Study.
    Chan YH; Wu LS; Chang SH; Lee HF; Liu JR; See LC; Yeh YH; Kuo CT
    PLoS One; 2016; 11(3):e0151485. PubMed ID: 26986069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 56.